肿瘤患者自身抗体抗SPAG9在外周血中的表达研究

目的:通过对肿瘤患者血清中抗原9(SPAG9)的自身抗体的检测,了解患者外周血中抗SPAG9自身抗体的表达情况。方法:利用SPAG9重组,确立ELISA检测肿瘤患者血清中抗SPAG9抗体的有效性,从而了解由SPAG9所诱发的患者体液免疫反应。采用的判断标准为:参照组血清中抗SPAG9抗体0D的均值加2倍SD作为阳性。结果:研究的90例肿瘤患者中,血清SPAG9免疫反应总体阳性率为32.3%,肝癌组阳性率为33.3%,肺癌组阳性率为17.9%,其他肿瘤组阳性率为50%,健康对照组为33.3%。结论:SPAG9自身抗体在不同的肿瘤患者外周血中有着不同程度的表达,此次研究具有一定的医学价值。

Objective： Through the tumor antigen 9 （SPAG9）in serum autoantibodies detection, understanding of peripheral blood in patients with resistant SPAG9 expression of autoantibodies. Methods： Using SPAG9 back together, establish the ELISA detection effectiveness of anti SPAG9 antibody in serum tumor patients, to understand the humoral immune response induced by SPAG9 patients. The judgment standard is： the control group in serum anti SPAG9 antibody 0 d average of 2 times the SD as positive. Results： 90 cases of tumor patients, the serum SPAG9 immune response total positive rate was 32.3%, positive rate of liver cancer group was 33.3%, positive rate of lung cancer group was 17.9%, positive rate was 50%, the other tumor group health control group is 33.3%. Conclusion： SPAG9 autoantibodies in different tumor patients have different degree of expression in peripheral blood, the research has some medicinal value.